ABSTRACT OBJECTIVES This study sought to determine if glucagon-like peptide (GLP)-1 ameliorates myocardial metabolic abnormalities in chronic heart failure.
A n increasing body of evidence indicates that advanced heart failure with reduced ejection fraction (HFrEF) is characterized by an impaired capacity of the myocardium to metabolize fatty acids. Furthermore, the changes in metabolism are associated with a reduction in high-energy phosphate content, changes in mitochondrial function, and increased dependence on glucose as a substrate (1) .
The basis for this shift toward glucose metabolism is unknown; however, it may serve as a compensatory mechanism for the generation of adequate adenosine triphosphate in the face of metabolic decompensation (2) (3) (4) .
Despite this shift, stores of high-energy phosphates decline and correspond to reductions in myocardial insulin sensitivity (5, 6) . This myocardial energy depletion is thought to be a key contributor to the progressive impairment in myocardial systolic function that characterizes HFrEF.
Glucagon-like peptide (GLP)-1 receptor activation
leads to insulinotropic and insulinomimetic effects in various tissues including the myocardium and has demonstrated beneficial effects on myocardial glucose uptake (7) (8) (9) (10) . Improved glucose uptake associated with GLP-1 administration has been shown to increase myocardial contractility in preclinical models of heart failure and in patients with HFrEF (8, 10, 11) . In several small studies, a continuous infusion of GLP-1 peptide increased exercise capacity (peak oxygen consumption [VO 2 ] and 6-min walk test [6MW] ) and left ventricular ejection fraction (LVEF) in subjects with chronic heart failure (12) , improved LVEF in patients with acute myocardial infarction (10) , and reduced the need for administration of intravenous pressor agents in patients following cardiac surgery (13) .
However, improvement in myocardial glucose uptake in HFrEF has been demonstrated using metabolically active agents that nonetheless have been reported to have adverse clinical effects (14, 15) . Whether the putative benefit of GLP-1 mimetics will translate into clinical benefit is of interest, and is under study in several clinical trials (NCT01425580, NCT01800968, NCT00766857 Subjects came to their respective study sites weekly for subcutaneous injections and study assessments, with final assessments performed at Week 13, and a follow-up visit 28 days after the last dose ( Figure 1) .
A total of 100 subjects were planned to complete this study (25 per 6MW. The 6MW was performed at baseline and Week 13 according to standard methodology (18) . All patients were given standardized instructions and the distance walked was measured.
PATIENT-REPORTED QUALITY OF LIFE. Patientreported quality of life was measured at baseline and Week 13 using a validated instrument, the Minnesota Living with Heart Failure Questionnaire (19, 20) . PHARMACOKINETICS. Trough plasma pharmacokinetic samples were taken at each clinic visit. Plasma concentrations of albiglutide were determined using a validated enzyme-linked immunosorbent assay.
Within-run precision ranged between 7.4 and 11.6%.
Bias ranged between -11.1 and -3.1%.
STATISTICAL ANALYSIS. A sample size of 100 subjects (25 subjects per arm) provided at least 90% power to detect a targeted increase (compared with placebo) in myocardial glucose use (15.2 mmol/100 g/min) (23,24), myocardial efficiency (1.4 Â 10 6 mm Hg$ml/min 2 (25), peak VO 2 (1.5 ml/kg/min) (26) , and LVEF (6%); and 61%
power to detect a 50-m improvement in 6MW (27) . The endpoints, after natural log transformation as appropriate, were analyzed using a mixed effects analysis of Accordingly, per protocol, randomization into these arms was discontinued, and all subsequent subjects were randomized in a 1:1 fashion to either albiglutide 30 mg weekly or placebo until the target enrollment in these treatment arms was complete. Eighty-one of 82 randomized subjects (97%) completed the study.
One placebo-treated subject withdrew before the follow-up visit. No subjects were withdrawn because of adverse events (AEs) ( Table 1) .
DEMOGRAPHICS AND BASELINE CHARACTERISTICS.
Subject characteristics were balanced across all treatment groups. Background medical management was consistent with recommendations for standard of care ( Table 2) .
EFFICACY BIOMARKERS OF HEART FAILURE SEVERITY AND MEASURES OF GLUCOSE
METABOLISM. B r a i n n a t r i u r e t i c p e p t i d e . There were no clinically meaningful changes in brain natriuretic peptide within or between treatment groups ( Table 3) . Table 5 .
Note that only a subset of randomized subjects underwent PET/CT, and not all eligible subjects underwent both 18 (100) Values are n or n (%). *Subject withdrawn because of not entering the follow-up period.
AE ¼ adverse event; SAE ¼ serious adverse event. The observed albiglutide plasma concentrations and peak VO 2 levels were modeled using a standard baseline E max model to determine if a relationship exists between albiglutide plasma concentrations and the peak VO 2 response. The results (Online Figure 1) suggest no relationship between albiglutide exposure and peak VO 2 .
SAFETY AND AEs
There were a total of 69 subjects with AEs: placebo, Values are mean AE SE.
6MWT ¼ 6-min walk test; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume; peak VO2 ¼ peak oxygen consumption; QoL ¼ quality of life; other abbreviations as in Table 3 . Values are mean AE SE.
Abbreviation as in Table 3 .
in peak VO 2 with milrinone (28) . However, in the PROMISE trial of oral milrinone, multiple measures of submaximal exercise or quality of life all demonstrated no improvement versus placebo (29) . The safety data demonstrated that albiglutide up to 30 mg weekly was generally well tolerated in nondiabetic patients with heart failure, and no new safety concerns were identified.
STUDY LIMITATIONS. This study has several important limitations imposed by the study design. The number of subjects studied was small, and the dura- 
